CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial...
Phase 2
Nashville, Tennessee, United States and 65 other locations
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...
Phase 1
Nashville, Tennessee, United States and 20 other locations
for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recu...
Phase 3
Nashville, Tennessee, United States and 77 other locations
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer...
Phase 3
Nashville, Tennessee, United States and 35 other locations
drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer...
Phase 1
Nashville, Tennessee, United States and 73 other locations
in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-re ...
Phase 1
Nashville, Tennessee, United States and 17 other locations
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors....
Phase 1
Nashville, Tennessee, United States and 8 other locations
who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, e....
Phase 1
Nashville, Tennessee, United States and 21 other locations
is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor...
Phase 1
Nashville, Tennessee, United States and 6 other locations
Phase.* Cohort A: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-treated)* Cohort B: Advanced or Metastatic Triple Negative ...
Phase 1, Phase 2
Nashville, Tennessee, United States and 15 other locations
Clinical trials
Research sites
Resources
Legal